JP2001524941A5 - - Google Patents

Download PDF

Info

Publication number
JP2001524941A5
JP2001524941A5 JP1998531191A JP53119198A JP2001524941A5 JP 2001524941 A5 JP2001524941 A5 JP 2001524941A5 JP 1998531191 A JP1998531191 A JP 1998531191A JP 53119198 A JP53119198 A JP 53119198A JP 2001524941 A5 JP2001524941 A5 JP 2001524941A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP1998531191A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001524941A (ja
Filing date
Publication date
Priority claimed from US08/782,219 external-priority patent/US6080383A/en
Application filed filed Critical
Publication of JP2001524941A publication Critical patent/JP2001524941A/ja
Publication of JP2001524941A5 publication Critical patent/JP2001524941A5/ja
Pending legal-status Critical Current

Links

JP53119198A 1997-01-13 1998-01-13 可溶性放射性有毒物質の酵素変換による、癌治療のための方法および組成物 Pending JP2001524941A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/782,219 US6080383A (en) 1997-01-13 1997-01-13 Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
US08/782,219 1997-01-13
PCT/US1998/000511 WO1998030247A1 (en) 1997-01-13 1998-01-13 A method and composition for cancer treatment by enzymatic conversion of soluble radioactive toxic agents

Publications (2)

Publication Number Publication Date
JP2001524941A JP2001524941A (ja) 2001-12-04
JP2001524941A5 true JP2001524941A5 (enExample) 2005-09-08

Family

ID=25125383

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53119198A Pending JP2001524941A (ja) 1997-01-13 1998-01-13 可溶性放射性有毒物質の酵素変換による、癌治療のための方法および組成物

Country Status (5)

Country Link
US (2) US6080383A (enExample)
EP (1) EP1047456A4 (enExample)
JP (1) JP2001524941A (enExample)
AU (1) AU5913198A (enExample)
WO (1) WO1998030247A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7807136B2 (en) * 1997-01-13 2010-10-05 David S. Rose Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic precipitates in the cancer
US20030068382A1 (en) * 1999-05-18 2003-04-10 Samuel Rose Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
CA2322969A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Methods to provoke anti-cancer immune responses
US7514067B2 (en) 2000-04-25 2009-04-07 President And Fellows Of Harvard College Methods for tumor diagnosis and therapy
US20030032675A1 (en) * 2001-02-15 2003-02-13 Franz G. Andrew Manufacture of thyroid hormone tablets having consistent active moiety amounts
US7067148B2 (en) * 2001-02-15 2006-06-27 King Pharmaceutical Research & Development, Inc. Stabilized pharmaceutical and thyroid hormone compositions and method of preparation
US20030224047A1 (en) * 2001-02-15 2003-12-04 Franz G. Andrew Levothyroxine compositions and methods
US6555581B1 (en) 2001-02-15 2003-04-29 Jones Pharma, Inc. Levothyroxine compositions and methods
US6565537B2 (en) * 2001-04-18 2003-05-20 Dennis R. Tollini Tube securing assembly
US20030180353A1 (en) * 2001-08-10 2003-09-25 Franz G. Andrew Stabilized pharmaceutical compositions
US20030190349A1 (en) * 2001-08-10 2003-10-09 Franz G. Andrew Methods of stabilizing pharmaceutical compositions
US20030198667A1 (en) * 2001-08-10 2003-10-23 Franz Andrew G. Methods of producing dispersible pharmaceutical compositions
US20030198672A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique triidothyronine plasma AUC properties
US20030203967A1 (en) * 2001-08-14 2003-10-30 Franz G. Andrew Levothyroxine compositions having unique Tmax properties
US20030195253A1 (en) * 2001-08-14 2003-10-16 Franz G. Andrew Unadsorbed levothyroxine pharmaceutical compositions, methods of making and methods of administration
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030199586A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Unique levothyroxine aqueous materials
US7101569B2 (en) 2001-08-14 2006-09-05 Franz G Andrew Methods of administering levothyroxine pharmaceutical compositions
US20030190350A1 (en) * 2001-10-29 2003-10-09 Franz G. Andrew Levothyroxine compositions having unique triiodothyronine Tmax properties
US7615221B2 (en) * 2004-07-23 2009-11-10 Oncologic, Inc. Compositions and methods for treating cancer
WO2021215952A1 (ru) 2020-04-24 2021-10-28 Общество С Ограниченной Ответственностью "Индженик" Способ получения частиц бактериофагов семейства levivirus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189470A (en) * 1973-01-30 1980-02-19 Bio-Response, Inc. Method for the continuous removal of a specific antibody from the lymph fluid in animals and humans
US3964467A (en) * 1973-01-30 1976-06-22 Bio Response Inc. Methods and apparatus for augmentation of the production of anti-bodies in animals and humans and the collection thereof
CA1041445A (en) * 1973-04-09 1978-10-31 Sam Rose Method and apparatus for continuous mass in vitro suspension culture of cells
EP0109861A3 (en) * 1982-11-23 1986-05-14 Bio-Response Inc. Method for isolating cells
IN165717B (enExample) * 1986-08-07 1989-12-23 Battelle Memorial Institute
US4861581A (en) * 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5589328A (en) * 1994-08-04 1996-12-31 Mahant; Vijay K. Chemiluminescence assays based on indoxyl substrates, thioindoxyl substrates and other substrates

Similar Documents

Publication Publication Date Title
JP2000509635A5 (enExample)
JP2000507042A5 (enExample)
JP2000509912A5 (enExample)
JP2000509637A5 (enExample)
JP2000509587A5 (enExample)
JP2000507369A5 (enExample)
JP2000507433A5 (enExample)
JP2000508866A5 (enExample)
JP2000508022A5 (enExample)
JP2000508841A5 (enExample)
JP2002501379A5 (enExample)
JP2001514522A5 (enExample)
JP2000508680A5 (enExample)
JP2001517982A5 (enExample)
JP2000509804A5 (enExample)
JP2000509853A5 (enExample)
JP2000509755A5 (enExample)
JP2000510969A5 (enExample)
JP2000508102A5 (enExample)
JP2000508836A5 (enExample)
JP2000509520A5 (enExample)
JP2000509818A5 (enExample)
JP2001524941A5 (enExample)
JP2000507434A5 (enExample)
JP2000508880A5 (enExample)